apomorphine (Apokyn, Uprima)
Jump to navigation
Jump to search
Introduction
Tradenames: Uprima, Apokyn
Indications
- treatment of Parkinson's disease (FDA approved 2004)
- treatment of acute hypomobility episode of advanced Parkinson's Disease[3]
- treatment of parkinsonism
- erectile dysfunction
Dosage
- 2-3 mg sublingually (Uprima) 15-30 minutes prior to intercourse*
- injectable (Apokyn) with an antiemetic
- trimethobenzamide (Tigan) 300 mg PO TID[2]
- start 3 days prior to apomorphine
- continue for at least 1st 2 months of apomorphine treatment
- trimethobenzamide (Tigan) 300 mg PO TID[2]
* discontinued by manufacturer because of high incidence of adverse effects (nausea/vomiting, hypotension, sedation)
Pharmacokinetics
- metabolized by COMT
Adverse effects
- nausea/vomiting#
- dizziness
- headache
- bradycardia
- hypotension
- fainting
- sedation
# most patients will need an antiemetic
- drug adverse effects of adrenergic receptor agonists
- drug adverse effects of dopaminergic receptor agonists
- drug adverse effects of sympathomimetic(s)
Drug interactions
Mechanism of action
- dopamine receptor agonist
- centrally-acting agent
More general terms
References
- ↑ Prescriber's Letter 7(5):28, May 2000 http://www.fda.gov/bbs/topics/answers/2004/ANS01284.htm
- ↑ 2.0 2.1 Prescriber's Letter 11(6):33 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200608&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Department of Veterans Affairs, VA National Formulary
restricted to neurology for treatment of acute hypomobility episode of advanced Parkinson's Disease.